The recent ‘CAR-TCR Solid Tumor Searchlight’ digital workshop brought together key thinkers in the realm of CAR-T cell therapy. The overarching aim? Understand why CAR-T’s success in haematological cancers hasn’t yet shifted to solid tumours.     Top Challenge: Receptor Design The rapid vanishing act of activated CAR-Ts in solid tumors is a significant concern.…Read more

The Future of CAR-T Therapy Christina Sumners delves into the groundbreaking advancements of CAR T cell therapy beyond blood cancers. With its potential stretching from lung cancer to kidney and bone cancer, experts are optimistic about its future applications.    Hopes in Lung Cancer Treatment  Historically, non-small cell lung cancer has remained a challenge, with…Read more

Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma The study “Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma” is the result of diligent work by renowned authors including Giorgio Gaglia, Megan L. Burger, Cecily C. Ritch, Peter K. Sorger, Tyler Jacks, and Sandro Santagata. Their…Read more

Combined disruption of T cell inflammatory regulators  Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells Adoptive T cell therapies, particularly CAR T cell therapy, have seen outstanding results against blood cancers. However, the fight against solid tumors has been more challenging, primarily due to T cell exhaustion. This exhaustion reduces the T…Read more